According to a new study published in the Journal of Clinical Medicine, “cannabis use was associated with a lower risk of hypertension and a lower number of metabolic disorders” among those with the Hepatitis C virus.
For the study researchers examined the relationship between current and/or lifetime cannabis use and metabolic disorders in a cohort of 6,364 subjects infected with HCV. The study is titled Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients.
“Using cross-sectional data from the French ANRS CO22 Hepather cohort, we used regression models to test for an inverse relationship between cannabis use and (i) dyslipidemia, (ii) hypertension, and (iii) the total number of metabolic disorders”, states the study.
“Among the 6364 participants in the study population, both former and current cannabis use were associated with a lower risk of hypertension and fewer metabolic disorders.”
Researchers state that these results “were independent of central obesity”, and that “cannabis use was not associated with dyslipidemia.”
“In people chronically infected with HCV, cannabis use was associated with a lower risk of hypertension and a lower number of metabolic disorders”, concludes the study. “Post-HCV cure studies are needed to confirm these findings using longitudinal data and to test whether they translate into reduced mortality in this population.”
The study’s full abstract can be found below:
Abstract
Background and Aims. Hepatitis C virus (HCV) infection is associated with the onset of metabolic disorders which constitute risk factors for liver disease progression. Their impact may persist after the HCV infection has been cured. Cannabis use is associated with a lower risk of obesity and diabetes in both general and HCV populations. The associations between cannabis use and both dyslipidemia and hypertension have not yet been studied in persons with chronic HCV infection. Methods. Using cross-sectional data from the French ANRS CO22 Hepather cohort, we used regression models to test for an inverse relationship between cannabis use and (i) dyslipidemia, (ii) hypertension, and (iii) the total number of metabolic disorders. Results. Among the 6364 participants in the study population, both former and current cannabis use were associated with a lower risk of hypertension and fewer metabolic disorders. These results were independent of central obesity. Cannabis use was not associated with dyslipidemia. Conclusions. In people chronically infected with HCV, cannabis use was associated with a lower risk of hypertension and a lower number of metabolic disorders. Post-HCV cure studies are needed to confirm these findings using longitudinal data and to test whether they translate into reduced mortality in this population.
Thank you for reading The Marijuana Herald!
